Lorazepam Injection Recalled for Out-of-Specification Impurities and Degradation
Hikma Pharmaceuticals is recalling 82,700 vials of Lorazepam Injection due to failed quality specifications for impurities and degradation. Lot #070096 (expired July 2023) was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of an injectable pharmaceutical due to failed quality specifications for impurities and degradation. The product represents a risk-of-harm product where injury has not yet been reported, qualifying it as High severity per the rubric.
Plain-English summary
Hikma Pharmaceuticals USA Inc. is recalling approximately 82,700 vials of Lorazepam Injection, USP, 4mg/mL. The affected lot is Lot #070096, which expired in July 2023 and was distributed nationwide in the United States.
The U.S. Food and Drug Administration issued this Class II recall after testing revealed the product failed quality specifications for impurities and degradation. The lorazepam did not meet standards for total related compounds present in the medication.
Out-of-specification impurity and degradation levels in a pharmaceutical can affect product safety and effectiveness. The presence of these issues in tested samples triggered the recall of the entire lot.
Hikma Pharmaceuticals USA Inc. is the manufacturer and recalling firm. The affected product is identified by NDC codes 0641-6045-25 (carton) and 0641-6045-01 (individual vial).
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Category
- Drug — Injectable Benzodiazepine
- Hazard
- Affected units
- 82,700
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 070096
- exp. date 07/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Hikma Pharmaceuticals USA Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · LORAZEPAM
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
Same manufacturer · Hikma Pharmaceuticals USA Inc.
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- SevereFDA Recalls Acetaminophen Injection Due to Labeling Mix-up
FDA (Drugs) · 2024-08-28
- HighMorphine Sulfate Ampuls Recalled for Expired Filters in Cartons
FDA (Drugs) · 2024-03-27
- HighGanciclovir injection vials contain mislabeled cladribine vials in cartons
FDA (Drugs) · 2023-01-04
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08